Prenatal Testing Has Identified Preterm Birth Signals
A new research study suggests that routine genetic screening might predict spontaneous preterm birth risk.
Updated on Sept. 29, 2026 in Pregnancy
Live Poll
Would you choose additional genetic screening if offered during your routine first-trimester prenatal testing?
Researchers have identified patterns in first-trimester prenatal testing data that may signal a risk of spontaneous preterm birth. The findings rely on analyzing cell-free DNA fragments from existing tests to provide earlier clinical insights.
Why it matters
Identifying these risks during the first trimester could help families and clinicians manage pregnancy health more proactively. This research seeks to leverage existing testing infrastructure to provide molecular insights without the need for additional blood draws.
The study analyzed end-motifs in cell-free DNA, achieving 94% sensitivity and 90% specificity in a validation cohort. A separate ongoing observational study in Vietnam currently includes 1,105 participants.
The players
Gene Solutions
A Singapore-based company that provides genetic testing and non-invasive prenatal screening platforms.
The details
The analysis uses the DNAsphere.AI platform to integrate machine learning with multi-omic data. By looking at recurring patterns at the ends of cell-free DNA fragments in first-trimester samples, the system detects molecular signals linked to preterm birth. This process functions as a secondary analysis of existing data from standard non-invasive prenatal testing, meaning no new medical procedures are required for patients to obtain these results.
Timeline
2018: Gene Solutions launched the triSure NIPT platform.
2022: The company expanded its portfolio to include maternal carrier screening.
2023: Screening for single-gene disorders and microdeletions was added.
September 29, 2026: The study results were published in AJOG Global Reports.
The Home Front
This development follows a trend of using machine learning to maximize the clinical value of existing prenatal genetic datasets. It aligns with ongoing efforts to shift from simple screening to predictive molecular monitoring in obstetric care.
Families interested in this technology should discuss current testing options and available screening portfolios with their obstetrician. Because the model is still investigational, you should not assume these predictive results are available as part of standard clinical care at this time.
The takeaway
Advancements in cfDNA analysis are creating new possibilities for early risk assessment during pregnancy. Expect future updates as Gene Solutions moves toward multinational validation studies and clinical integration of this investigational tool.
Further reading
Learn more about the latest innovations in Pregnancy and prenatal care.
More information
You can review the Full study article in AJOG Global Reports for the complete findings.
Source note: This article includes information reported by Antara News.
Live Poll
Would you choose additional genetic screening if offered during your routine first-trimester prenatal testing?
